Celldex’s CSU drug could challenge a Novartis candidate after PhII

2024-02-26

临床2期临床结果

Celldex Therapeutics’ anti-KIT antibody hit the primary endpoint in a mid-stage test in chronic spontaneous urticaria, with some analysts describing the data as better than a Novartis therapy that’s further ahead in development.

Celldex’s Phase II trial set three doses of barzolvolimab against placebo in 208 patients with chronic spontaneous urticaria (CSU) who were symptomatic despite antihistamine treatment, including some who were refractory to biologics such as Novartis and Genentech’s Xolair. There are currently no approved treatments for patients whose disease is not controlled by Xolair.

Celldex’s CSU drug could challenge a Novartis candidate after PhII

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构